

No: 26.../2026/CBTT-NTF

Nghe An, date 11 month 6.. year 2026

EXTRAORDINARY INFORMATION DISCLOSURE

To: - State Securities Commission;
- Hanoi Stock Exchange.

I. Disclosing Organization

- Organization Name: Nghe An Pharmaceutical Medical Material and Equipment Joint Stock Company ("the Company")
- Stock Code: NTF
- Head Office Address: No. 16, Nguyen Thi Minh Khai, Thanh Vinh Ward, Nghe An Province
- Phone: 0238 384 1642 Fax: 038 3848720
- Email: dna@dnapharma.com.vn

II. Contents of Information Disclosure

Nghe An Pharmaceutical Medical Material And Equipment Joint Stock Company announces information on the report of changes in the method of using capital/money earned from sales. The Company announces this extraordinary information in accordance with Clause 1, Article 11 of Circular No. 96/2020/TT-BTC dated November 16, 2020.

III. Disclosure Website

This information was published on the website of Nghe An Pharmaceutical Medical Material And Equipment Joint Stock Company on June 11, 2026, at the following link:

<https://dnapharma.com.vn/quan-he-co-dong>

We hereby commit that the information published above is true and accurate and we assume full legal responsibility for the content of the published information./.

Attached documents:

- Resolution No. 43/2026/NQ-HĐQT;
- Report on changes to the plan for using the funds/proceeds from the offering.

**LEGAL REPRESENTATIVE / AUTHORIZED
PERSON FOR INFORMATION DISCLOSURE**



Nguyễn Đình Thành

NGHE AN PHARMACEUTICAL MEDICAL
MATERIALS AND EQUIPMENT
JOINT STOCK COMPANY

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 43/2026/NQ-HDQT

Nghe An, date 11 month 6 year 2026

RESOLUTION

THE BOARD OF DIRECTORS OF

NGHE AN PHARMACEUTICAL MEDICAL
MATERIALS AND EQUIPMENT JOINT STOCK COMPANY

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020; Law No. 76/2025/QH15 adopted on June 17, 2025 amending and supplementing a number of articles of the Law on Enterprises, and the implementing regulations thereof;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019; Law No. 56/2024/QH15 dated November 29, 2024 amending and supplementing a number of articles of the Law on Securities, and the implementing regulations thereof;
- Pursuant to the Charter of Nghe An Pharmaceutical Medical Materials and Equipment Joint Stock Company (the "Company");
- Pursuant to the Resolution of the Annual General Meeting of Shareholders of the Company dated May 29, 2025;
- Pursuant to Resolution No. 58/2025/NQ-HDQT dated November 27, 2025 of the Board of Directors ("Resolution No. 58"), approving the detailed plan for the use of proceeds from the public offering of shares to existing shareholders for the purpose of increasing the Company's charter capital;
- Pursuant to the Minutes of the Meeting No. 42/2026/BB-HDQT dated 11/6/2026 of the Board of Directors of Nghe An Pharmaceutical Medical Materials and Equipment Joint Stock Company.

HEREBY RESOLVES:

Article 1. The Board of Directors (the "Board") hereby adopts this Resolution with a 100% affirmative vote, as follows:

1. Resolution No. 1: To approve the amendment to the plan for the use of proceeds previously approved under the Resolution of the Annual General Meeting of Shareholders dated May 29, 2025 and Resolution No. 58, with the following details:

1.1. Original plan for the use of proceeds:

No.	Use of proceeds	Proposed allocation (VND)	Expected disbursement schedule
	Construction of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park	82,000,000,000	4 th Quarter of 2025 – 2 nd Quarter of 2026
1	Factory building 01	14,977,931,196	4 th Quarter of 2025 – 2 nd Quarter of 2026
2	Factory building 02	8,367,750,008	4 th Quarter of 2025 – 2 nd Quarter of 2026
3	Factory building 03	3,919,069,190	4 th Quarter of 2025 – 2 nd Quarter of 2026
4	Factory building 04	3,628,060,694	4 th Quarter of 2025 – 2 nd Quarter of 2026
5	Factory building 05	4,744,855,649	4 th Quarter of 2025 – 2 nd Quarter of 2026



No.	Use of proceeds	Proposed allocation (VND)	Expected disbursement schedule
6	Office building 05A	15,429,230,592	4 th Quarter of 2025 – 2 nd Quarter of 2026
7	Factory building 06	20,073,408,205	4 th Quarter of 2025 – 2 nd Quarter of 2026
8	External auxiliary facilities	3,762,464,582	4 th Quarter of 2025 – 2 nd Quarter of 2026
9	Ground levelling	516,241,931	4 th Quarter of 2025 – 2 nd Quarter of 2026
10	Transportation	6,580,987,953	4 th Quarter of 2025 – 2 nd Quarter of 2026
II	Supplementation of working capital for the payment of raw materials and goods serving production and business operations	8,000,000,000	4 th Quarter of 2025 – 2 nd Quarter of 2026
	Total	90,000,000,000	

1.2. Amended plan for the use of proceeds: To place 40,000,000,000 VND (*in words: Forty billion Vietnamese Dong, representing 44.44% of the total proceeds from the share offering*), on fixed-term deposit. This amount forms part of the 82 billion VND originally allocated for the construction activities of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park (the “**Project**”) and will be deposited during the period in which such funds have not yet been utilized or are pending disbursement for the Project's construction activities, with a view to ensuring the efficient use of capital.

1.3. Reason for the amendment: The Company is currently considering adjustments to certain components of the Project and, accordingly, has not proceeded with the implementation of the relevant construction items and work packages.

2. Resolution No. 2: The Board of Directors authorizes the Deputy Director in charge of the Company to undertake all necessary actions and procedures for the implementation of the policy approved by the Board of Directors as set out above, in accordance with applicable laws.

Article 2. This Resolution shall take effect as of the date of its signing. The members of the Board of Directors, the Board of Management, the Company's departments/divisions and affiliated units, and all relevant individuals shall be responsible for the implementation of this Resolution./.

Recipients:

- Members of the Board of Directors,
- Board of Supervisors;
- File in the archives.

ON BEHALF OF THE BOARD OF DIRECTORS (Signed)
CHAIRPERSON OF THE BOARD OF DIRECTORS



(Signed)
Nguyễn Văn Thang



**NGHE AN PHARMACEUTICAL MEDICAL
MATERIALS AND EQUIPMENT
JOINT STOCK COMPANY**

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No. 225/2026/BC-DNA

Nghe An, date 11 month 06 year 2026

**REPORT ON THE AMENDMENT TO THE PLAN FOR THE USE OF PROCEEDS/FUNDS
RAISED FROM THE OFFERING**

*(Pursuant to the Certificate of Registration for the Public Offering of Additional Shares No. 553/GCN-UBCK
issued by the State Securities Commission on December 26, 2025)*

To: The State Securities Commission

I. INFORMATION ON THE ISSUER

1. Full name of the issuer: NGHE AN PHARMACEUTICAL MEDICAL MATERIALS AND EQUIPMENT JOINT STOCK COMPANY

2. Head office address: No. 16, Nguyen Thi Minh Khai Street, Thanh Vinh Ward, Nghe An Province, Vietnam.

3. Phone: 0238 384 4741

Fax: 0238 384 8720

Website: <https://dnapharma.com.vn/>

4. Charter capital: 150,000,000,000 VND.

5. Stock ticker symbol (if any): NTF

6. Bank where the payment account is maintained: Southeast Asia Commercial Joint Stock Bank
Account Number: 888003455899

7. Enterprise Registration Certificate bearing Enterprise Code No. 2900491298, initially issued by the Business Registration Division under the Department of Planning and Investment of Nghe An Province on January 30, 2002, and amended for the 14th time by the Business Registration Division under the Department of Finance of Nghe An Province on March 27, 2026.

- Principal business line: Manufacturing of pharmaceuticals, medicinal chemicals and botanical products.

Business line code: 2100.

- Principal products/services: Manufacture of pharmaceutical products, health supplements, micronutrient-fortified foods, medicinal chemicals, medicinal herbs, pharmaceutical raw materials and excipients, and processing of medicinal herbs.

8. Establishment and Operation Licenses (if required under specialized laws):

- Decision No. 1206/QD-BYT, issued by the Ministry of Health on May 16, 2022, regarding the issuance of the Certificate of Eligibility for Pharmaceutical Business to Nghe An Pharmaceutical Medical Materials and Equipment Joint Stock Company (DNA PHARMA);

- Decision No. 602/QD-QLD, issued by the Drug Administration of Vietnam under the Ministry of Health on August 15, 2023, regarding the issuance of the Good Manufacturing Practice Certificate for Medicinal Products and Pharmaceutical Ingredients to Nghe An Pharmaceutical Medical Materials and Equipment Joint Stock Company (DNA PHARMA);

- Certificate of Good Distribution Practice (GDP) for Medicinal Products and Pharmaceutical Ingredients No. 02/08/GDP, issued by the Nghe An Department of Health on June 21, 2024.

II. SECURITIES OFFERED

1. Name of the securities: Shares of Nghe An Pharmaceutical Medical Materials and Equipment Joint Stock Company.
2. Type of securities: Common shares
3. Par value: 10,000 VND per share (*Ten thousand Vietnamese Dong*).
4. Number of securities issued: 9,000,000 shares (*Nine million shares*).
5. Total capital/funds raised: 90,000,000,000 VND (*Ninety billion Vietnamese Dong*), of which 82,000,000,000 VND (*Eighty-two billion Vietnamese Dong*) is allocated for the project.
6. Closing date of the offering: March 11, 2026.

III. PLAN FOR THE USE OF PROCEEDS/FUNDS RAISED FROM THE OFFERING

1. Plan for the use of proceeds/funds raised from the offering: Pursuant to the Resolution of the 2025 Annual General Meeting of Shareholders adopted on May 29, 2025 and the Board of Directors' Resolution No. 58/2025/NQ-HDQT dated November 27, 2025 on approving the detailed plan for the use of proceeds from the public offering of shares to existing shareholders for the purpose of increasing the Company's charter capital:

No.	Use of proceeds	Proposed allocation (VND)	Expected disbursement schedule
	Construction of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park	82,000,000,000	4th Quarter of 2025 – 2nd Quarter of 2026
1	Factory building 01	14,977,931,196	4 th Quarter of 2025 – 2 nd Quarter of 2026
2	Factory building 02	8,367,750,008	4 th Quarter of 2025 – 2 nd Quarter of 2026
3	Factory building 03	3,919,069,190	4 th Quarter of 2025 – 2 nd Quarter of 2026
4	Factory building 04	3,628,060,694	4 th Quarter of 2025 – 2 nd Quarter of 2026
5	Factory building 05	4,744,855,649	4 th Quarter of 2025 – 2 nd Quarter of 2026
6	Office building 05A	15,429,230,592	4 th Quarter of 2025 – 2 nd Quarter of 2026
7	Factory building 06	20,073,408,205	4 th Quarter of 2025 – 2 nd Quarter of 2026
8	External auxiliary facilities	3,762,464,582	4 th Quarter of 2025 – 2 nd Quarter of 2026
9	Ground levelling	516,241,931	4 th Quarter of 2025 – 2 nd Quarter of 2026
10	Transportation	6,580,987,953	4 th Quarter of 2025 – 2 nd Quarter of 2026
II	Supplementation of working capital for the payment of raw materials and goods serving production and business operations	8,000,000,000	4th Quarter of 2025 – 2nd Quarter of 2026
	Total	90,000,000,000	



2. Amended plan for the use of proceeds: To place 40,000,000,000 VND (in words: Forty billion Vietnamese Dong, representing 44.44% of the total proceeds from the share offering), on fixed-term deposit. This amount forms part of the 82 billion VND originally allocated for the construction activities of the Nghe An Pharmaceutical Manufacturing Plant Project at Bac Vinh Industrial Park (the “Project”) and will be deposited during the period in which such funds have not yet been utilized or are pending disbursement for the Project's construction activities, with a view to ensuring the efficient use of capital.

3. Reason for the amendment: The Company is currently considering adjustments to certain components of the Project and, accordingly, has not proceeded with the implementation of the relevant construction items and work packages.

4. Basis for the change: Resolution of the Board of Directors No. 43./2026/NQ-HDQT dated 11/06/2026 of Nghe An Pharmaceutical Medical Materials and Equipment Joint Stock Company.

5. The proposed change will be published at: Company website: <https://dnapharma.com.vn/>; Hanoi Stock Exchange Information Management System: <https://cims.hnx.vn/>; Securities Market Information Disclosure System of the State Securities Commission: <https://ids.ssc.gov.vn>

Date 11 month 06 year 2026

NGHE AN PHARMACEUTICAL MEDICAL MATERIALS
AND EQUIPMENT JOINT STOCK COMPANY (Signed)

(Legal Representative)

(Signature, full name and seal)

(Signed)

